Group 1 - The core point of the article is that Konomai successfully completed a new round of strategic financing amounting to several tens of millions of RMB in January 2026 [1] - The financing was exclusively funded by the Beijing Pharmaceutical and Health Industry Investment Fund [1]

Group 1 - The company, Chengda Biological, announced the establishment of a biomedical industry investment fund in collaboration with its controlling shareholder, Liaoning Chengda, and its subsidiaries, aiming to enhance its competitive edge and capitalize on opportunities in the biopharmaceutical industry [1][2] - The total scale of the fund is set to not exceed 100 million yuan, with an initial size of 50.2 million yuan. The fund will be managed by Chengda Coastal, which will contribute 1 million yuan, representing approximately 0.1992% of the initial fund size [1] - Chengda Biological plans to contribute 40 million yuan, accounting for about 79.6813% of the initial fund size, while Liaoning Chengda will contribute 10 million yuan, representing approximately 19.9203% [1] Group 2 - The fund will focus on investments in the life and health sector during its investment period, with further capital contributions expected to reach the total commitment of 100 million yuan within three years [2] - The fund is currently in the planning stage, and the partnership agreement has not yet been formally signed, meaning that the investment shares are subject to the final agreement [2] - The company's board of directors has proposed to authorize the management to handle all matters related to this external investment, including timely progress on the fund's establishment and registration [2]

Core Viewpoint - The company, Boten Co., Ltd. (300363.SZ), plans to acquire a portion of shares in Shenzhen Yifeng Yunding Venture Capital Partnership (Limited Partnership) for a nominal price of 1 yuan, which will involve a capital contribution obligation of 20 million yuan as per the partnership agreement [1] Group 1: Investment Details - The acquisition will allow the company to indirectly invest in Hangzhou Yifeng Runjun Venture Capital Partnership (Limited Partnership) through the Yifeng Yunding Fund [1] - The Yifeng Yunding Fund specializes in investments in the healthcare sector, focusing on innovative drugs, high-end medical devices, and biotechnology [1] Group 2: Strategic Implications - This investment is expected to leverage the resources of a professional investment institution, aiding the company in business development and strategic resource acquisition [1] - The projects funded by the Yifeng Runjun Fund may present opportunities for business collaboration and synergies with the company [1]

Core Viewpoint - The company, Boten Co., Ltd. (300363.SZ), plans to acquire a portion of shares in Shenzhen Yifeng Yunding Venture Capital Partnership (Limited Partnership) for a nominal price of 1 yuan, which will involve a capital contribution obligation of 20 million yuan as per the partnership agreement [1] Group 1: Investment Details - The acquisition will allow the company to indirectly invest in Hangzhou Yifeng Runjun Venture Capital Partnership (Limited Partnership) through the Yifeng Yunding Fund [1] - The Yifeng Yunding Fund specializes in investments in the healthcare sector, focusing on innovative drugs, high-end medical devices, and biotechnology [1] Group 2: Strategic Implications - This investment is expected to leverage the resources of a professional investment institution, aiding the company in business development and strategic resource acquisition [1] - The projects funded by the Yifeng Runjun Fund may present opportunities for business collaboration and synergies with the company [1]

Core Viewpoint - The company has announced the establishment of an industrial fund to enhance strategic development and capitalize on investment opportunities in the biopharmaceutical sector [1] Group 1: Investment Details - The company will collaborate with Guangzhou Nanyue Aoyang Fund Management Co., Ltd. and Guangzhou Nanyue Fund Group Co., Ltd. to set up the Guangzhou Zengcheng Nante Biopharmaceutical Investment Partnership (Limited Partnership) [1] - The total investment amount for the industrial fund is RMB 50.01 million, with the company contributing RMB 25 million, accounting for 49.99% of the total subscription [1] - The fund will primarily invest in early and mid-stage biopharmaceutical projects [1] Group 2: Regulatory Compliance - The investment partnership has completed the filing procedures with the Asset Management Association of China and has obtained the Private Investment Fund Filing Certificate [1]

Core Viewpoint - The article highlights the ongoing efforts of Shanghai Guotou Company in promoting the biopharmaceutical industry through the establishment of various funds aimed at supporting innovation and capital infusion in the sector [1][2]. Group 1: Fund Establishment and Goals - The Shanghai Guotou Company has signed agreements with 10 institutions to further develop its biopharmaceutical industry fund matrix, marking a significant step in its capital management strategy [1]. - A total of 22.5 billion yuan has been committed to the Shanghai Biopharmaceutical M&A Fund, with the aim of enhancing the industry through strategic investments and mergers [2]. - The Shanghai Biopharmaceutical Industry Mother Fund, with a total scale of 22.5 billion yuan, aims to support the entire innovation chain of the biopharmaceutical industry [1][2]. Group 2: Industry Growth and Performance - Since 2021, the Shanghai biopharmaceutical industry has seen a compound annual growth rate of 8.94%, with the industry scale increasing from 761.71 billion yuan in 2021 to 984.70 billion yuan in 2024 [3]. - The industry scale reached 500.57 billion yuan in the first half of 2025, with projections indicating it will surpass one trillion yuan by the end of the year [3]. Group 3: Event Structure and Activities - The 2025 Shanghai International Biopharmaceutical Week features a structured layout of activities, including one opening event, one exhibition, and 15 thematic forums focused on various aspects of the biopharmaceutical industry [2]. - The event aims to create a year-round platform for ongoing activities related to innovation, policy, and capital in the biopharmaceutical sector [2].

Core Viewpoint - The company Zhaoyan New Drug announced its intention to establish a seed fund in partnership with Yifeng Capital and Yifeng Mingyuan, focusing on investments in the biomedicine and high-end medical device sectors, with a total fundraising target of 12.75 million RMB [2][3]. Group 1: Company Overview - Zhaoyan New Drug, founded in 1995, is a specialized contract research organization (CRO) headquartered in Beijing, with over 2,500 professionals across multiple locations including Beijing, Suzhou, and the United States [3][4]. - The company is listed on both A-share and Hong Kong stock markets, categorized as an "A+H" enterprise [4]. Group 2: Investment Details - The seed fund will have a total fundraising scale of 12.75 million RMB, with Zhaoyan New Drug or its designated subsidiary committing up to 10 million RMB as a limited partner (LP) [2]. - The fund aims to support strategic emerging industries and key sectors prioritized by the Shenzhen government, particularly in biomedicine and high-end medical devices [3]. Group 3: Partner Information - Yifeng Capital, established in 2012, focuses on investments in the biomedicine sector and is recognized as one of the top venture capital institutions in Shenzhen [2][3]. - The investment portfolio of Yifeng Capital includes several successful companies that have gone public, such as Microchip Biotech and Apexigen [3].

Core Viewpoint - Jiet Bio plans to establish an industrial fund to invest in early and mid-stage biopharmaceutical projects, with a total fund size of 50.01 million yuan [1] Investment Details - The fund will be initiated in partnership with Guangzhou Nanyue Aoyang Fund Management Co., Ltd. and Guangzhou Nanyue Fund Group Co., Ltd. [1] - Jiet Bio intends to contribute 25 million yuan, representing a 49.99% stake in the fund [1] - The partnership will have a duration of 7 years, with the first 4 years designated for investment and the last 3 years for exit [1] Transaction Nature - The investment does not constitute a related party transaction or a major asset restructuring [1]